Back to top
more

Lantheus (LNTH)

(Real Time Quote from BATS)

$64.18 USD

64.18
22,756

-1.03 (-1.58%)

Updated Apr 25, 2024 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) reachead $65.21 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

by Zacks Equity Research

Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.

Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Is Lantheus (LNTH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?

by Zacks Equity Research

Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Elevance Health (ELV), CD&R to Unveil Primary Care Offering

by Zacks Equity Research

Elevance Health (ELV) forms an alliance with CD&R to enhance primary care delivery by making collective use of the partners' assets and subsequently, reduce overall costs of care.

Lantheus Holdings (LNTH) Stock Moves -0.89%: What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) closed the most recent trading day at $60.25, moving -0.89% from the previous trading session.

Here's Why Lantheus Holdings (LNTH) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Lantheus Holdings (LNTH) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

Lantheus Holdings (LNTH) reachead $60.42 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.

Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.

Why You Should Add Ensign Group (ENSG) to Your Portfolio Now

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth on sustained top-line growth, a growing healthcare portfolio and solid operating cash flows.

Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now?

by Zacks Equity Research

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the closing of the recent trading day, Lantheus Holdings (LNTH) stood at $59.19, denoting a +0.54% change from the preceding trading day.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

Acadia (ACHC) Starts Construction of Malden's JV Facility

by Zacks Equity Research

Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.